Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Acta Pharmaciae Indonesia : Acta Pharm Indo Majalah Farmaseutik
Krisnadewi, Kadek Ida
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Estimasi Nilai Years of Life Lost (YLL) Penyakit Kanker Akibat Secondhand Smoke di Indonesia Kadek Ida Krisnadewi; Susi Ari Kristina; Chirun Wiedyaningsih
Majalah Farmaseutik Vol 16, No 2 (2020)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (304.98 KB) | DOI: 10.22146/farmaseutik.v16i2.49615

Abstract

Paparan rokok pada perokok pasif  meningkatkan risiko terjadinya penyakit jantung koroner dan stroke pada orang dewasa, dan juga gangguan pernafasan hingga kematian pada anak-anak. Perokok pasif menjadi penyebab 42.000 kematian pada kanker, dan sebanyak 7000 lebih kematian disebabkan oleh kanker paru. Tujuan penelitian ini adalah menghitung beban ekonomi dari sisi Years of Life Lost (YLL). Estimasi nilai years of life lost  (YLL) untuk 6 penyakit kanker akibat perokok pasif diambil per kelompok jenis kelamin. YLL dihitung dengan mengalikan angka harapan hidup menurut standar WHO Life table dan estimasi kematian akibat kanker.Diperoleh hasil nilai YLL laki-laki dan perempuan apabila dijumlahkan yakni, nilai terbesar ialah pada kanker paru-paru (19.823 person years), diikuti dengan kanker kolon (19.007 person years), kanker pankreas (14.155 person years), kanker perut (3.372 person years), kanker kandung kemih (3.251 person years) dan kanker laring (1.242 person years). Kesimpulannya, terdapat 3 penyakit kanker akibat perokok pasif yang menimbulkan jumlah kehilangan tahun (akibat kematian dini YLL) terbesar ialah kanker paru-paru, kanker kolon dan kanker pankreas. Pertimbangan indikator YLL penting dilakukan sebagai sumber informasi dalam penentu kebijakan. Nilai YLL dari kanker paru cukup tinggi, hal ini perlu menjadi perhatian serius bagi pemerintah dan tenaga kesehatan agar lebih mewaspadai dan menghimbau terkait bahayanya paparan perokok pasif bagi masyarakat.
Cost-effectiveness analysis of lopinavir, ritonavir, and nevirapine toward HIV AIDS patients as antiretroviral: a systematic review Pratama, Anggara Martha; Pramestutie, Hananditia Rachma; Krisnadewi, Kadek Ida; Pratiwi, Hening
Acta Pharmaciae Indonesia Vol 11 No 2 (2023): Acta Pharmaciae Indonesia: Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2023.11.2.6916

Abstract

Background: The mobilization of resources to prevent and treat human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) is unparalleled in the history of public health. Nevirapine resistance may decrease the effectiveness of viral suppression with nevirapine-based HIV in women infected with human immunodeficiency virus (HIV) with previous exposure to single-dose nevirapine. However, the alternative lopinavir/ritonavir–based antiretroviral therapy (ART) regimen is more expensive. Objective: Our objectives were to project the tradeoffs regarding the cost-effectiveness of ART regimens for nevirapine-exposed and lopinavir/ritonavir. Methods: A thorough literature search was conducted using PubMed and SAGE databases, employing search terms such as “cost-effectiveness analysis,” AND “HIV AIDS,” AND “lopinavir,” OR “ritonavir,” AND “nevirapine.” Additionally, hand searches were carried out on Google Scholar with various combinations of these terms to ensure comprehensive coverage of relevant studies. Results: Six studies met the our inclusion criteria and were reviewed. The analysis confirms that both nevirapine and lopinavir/ritonavir-based ART regimens are cost effective in a range of settings, despite differences in their relative efficacy and contexts in which they are used. Conclusion: This systematic review collates recent studies on the cost-effectiveness of nevirapine and lopinavir/ritonavir in ART. It showed that in this finding, there are cost effective but this article had wide variation with comparison therapy. Cost-effectiveness results depended on the relative efficacy of lopinavir/ritonavir and nevirapine in both first-line and second-line ART.
Co-Authors Chirun Wiedyaningsih Hening Pratiwi, Hening pramestutie, hananditia rachma Pratama, Anggara Martha Susi Ari Kristina